MedTrace Logo

Rizatriptan 10 MG RPD in the Treatment of Acute Migraine

NCT01057160 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 195

Last updated 2013-01-28

No results posted yet for this study

Summary

This is a multicentre, open label, prospective, randomized, two-attack study with active comparator in patients reporting inadequate response to analgesics and/or triptans to examine the efficacy of Rizatriptan 10 mg RPD in this group of patients.

Conditions

Interventions

DRUG

Rizatriptan

use of rizatriptan 10 mg for one migraine attack, in comparison to previously used analgetic

Sponsors & Collaborators

Principal Investigators

  • Hans-Christoph Diener, Prof. · Department of Neurology, University Essen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2010-06-30
Completion
2010-06-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01057160 on ClinicalTrials.gov